Sign in to view content

Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model

Andrew A. Moshfeghi, MD, MBA, FASRS

Video
Published 2021

Related

Episode 25: RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD with Dr. Mark Gillies
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019

Category: Diabetic Retinopathy

See more